Is ELUTIA INC. (ELUT) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 53.1% / 30% | 28.4% / 30% | 15.1% / 30% | 102.81% / 5% | ✗ NOT HALAL |
| DJIM | 53.1% / 33% | 28.4% / 33% | 15.1% / 33% | 102.81% / 5% | ✗ NOT HALAL |
| MSCI | 68.5% / 33% | 36.6% / 33% | 19.5% / 33% | 102.81% / 5% | ✗ NOT HALAL |
| S&P | 53.1% / 33% | 28.4% / 33% | 15.1% / 33% | 102.81% / 5% | ✗ NOT HALAL |
| FTSE | 68.5% / 33% | 36.6% / 33% | 19.5% / 50% | 102.81% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 53.7% | |
| Operating Margin | -167.9% | |
| Net Margin | 434.2% | |
| Return on Assets (ROA) | -23.4% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$45M |
| Free Cash Flow | -$47M |
| Total Debt | $4M |
| Debt-to-Equity | 14.2 |
| Current Ratio | 2.2 |
| Total Assets | $62M |
Price & Trading
| Last Close | $1.07 |
| 50-Day MA | $1.05 |
| 200-Day MA | $1.25 |
| Avg Volume | 296K |
| Beta | 0.7 |
|
52-Week Range
$0.50
| |
About ELUTIA INC. (ELUT)
Elutia Inc., a commercial-stage company, focuses on developing drug-eluting biomatrix products for use in surgical reconstruction and related applications. The company operates in two segments, Women's Health and Cardiovascular. Its lead development programs include NXT-41 and NXT-41x, which are designed as biologic scaffolds combined with local antibiotic delivery. The company provides SimpliDerm, a human acellular dermal matrix used in soft tissue reconstruction. It also offers ProxiCor for cardiac tissue repair for use as an intracardiac patch for repairs, such as atrial and ventricular septal defects and suture-line buttressing, and pledgets, as well as for pericardial closure to reconstruct the pericardium after heart surgery. In addition, the company provides Tyke, a thinner pliable matrix for the repair of pericardial structures for neonates and infants; as an epicardial for damaged or repaired cardiac structures; and as a patch material for cardiac defects, as well as VasCure, a patch material to repair or reconstruct the peripheral vasculature. The company sells its products directly to hospitals and other healthcare facilities through independent sales agents. The company was formerly known as Aziyo Biologics, Inc. and changed its name to Elutia Inc. in September 2023. Elutia Inc. was incorporated in 2015 and is headquartered in Gaithersburg, Maryland.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is ELUTIA INC. (ELUT) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), ELUTIA INC. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is ELUTIA INC.'s debt ratio?
ELUTIA INC.'s debt ratio is 53.1% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 68.5%.
What are ELUTIA INC.'s key financial metrics?
ELUTIA INC. has a market capitalization of $46M, and revenue of $12M. The company maintains a gross margin of 53.7% and a net margin of 434.2%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.